{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:02:38Z","timestamp":1782831758173,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K07951"],"award-info":[{"award-number":["23K07951"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K08936"],"award-info":[{"award-number":["19K08936"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJSP2123"],"award-info":[{"award-number":["JPMJSP2123"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019271","name":"Kyorin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031489","name":"Shionogi Infectious Disease Research Promotion Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031489","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi and Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007467","name":"School of Medicine, Keio University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007467","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jgar.2025.02.015","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T12:25:22Z","timestamp":1740486322000},"page":"142-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Combined dual \u03b2-lactams and diazabicyclooctane \u03b2-lactamase inhibitor is highly effective against Mycobacterium abscessus species in vitro"],"prefix":"10.1016","volume":"42","author":[{"given":"Kana","family":"Misawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9662-5694","authenticated-orcid":false,"given":"Tomoyasu","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Shimamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Kashimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Enoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5462-1684","authenticated-orcid":false,"given":"Kazuaki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.02.015_bib0001","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijid.2022.10.013","article-title":"Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review","volume":"125","author":"Dahl","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2025.02.015_bib0002","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41579-020-0331-1","article-title":"Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus","volume":"18","author":"Johansen","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jgar.2025.02.015_bib0003","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1513\/AnnalsATS.201804-236OC","article-title":"Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. Managed Care Health Plan, 2008-2015","volume":"17","author":"Winthrop","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jgar.2025.02.015_bib0004","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3201\/eid2206.151086","article-title":"Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan1","volume":"22","author":"Namkoong","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jgar.2025.02.015_bib0005","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jgar.2025.02.015_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01206-17","article-title":"Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence","volume":"61","author":"Pasipanodya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.02.015_bib0007","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1128\/AAC.01275-08","article-title":"A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae","volume":"53","author":"Nash","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.02.015_bib0008","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/jac\/dkt410","article-title":"Characterization of broad-spectrum Mycobacterium abscessus class A \u03b2-lactamase","volume":"69","author":"Soroka","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.02.015_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02440-16","article-title":"Inhibition of the \u03b2-lactamase BlaMab by avibactam improves the in vitro and in vivo efficacy of imipenem against Mycobacterium abscessus","volume":"61","author":"Lefebvre","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.02.015_bib0010","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2217\/fmb-2016-0234","article-title":"Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus","volume":"12","author":"Kaushik","year":"2017","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jgar.2025.02.015_bib0011","first-page":"1","article-title":"In vitro activity of the new \u03b2-lactamase inhibitors relebactam and vaborbactam in combination with \u03b2-lactams against Mycobacterium abscessus complex clinical isolates","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.02.015_bib0012","first-page":"1","article-title":"New \u03b2-lactamase inhibitors nacubactam and zidebactam improve the In vitro activity of \u03b2-lactam antibiotics Against Mycobacterium abscessus complex clinical isolates","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.02.015_bib0013","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03529-21","article-title":"Inhibiting Mycobacterium abscessus cell Wall synthesis: using a novel diazabicyclooctane \u03b2-lactamase inhibitor to augment \u03b2-lactam action","volume":"13","author":"Dousa","year":"2022","journal-title":"MBio"},{"key":"10.1016\/j.jgar.2025.02.015_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106669","article-title":"In vitro effects of diazabicyclooctane \u03b2-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex","volume":"60","author":"Misawa","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.02.015_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mBio.02895-18","article-title":"Dual \u03b2-lactam combinations highly active against Mycobacterium abscessus complex in vitro","volume":"10","author":"Pandey","year":"2019","journal-title":"MBio"},{"key":"10.1016\/j.jgar.2025.02.015_bib0016","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00098-20","article-title":"Insights into the <scp>l<\/scp>, <scp>d<\/scp>-transpeptidases and <scp>d<\/scp>, <scp>d<\/scp>-carboxypeptidase of Mycobacterium abscessus: ceftaroline, imipenem, and novel diazabicyclooctane inhibitors","volume":"64","author":"Dousa","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.02.015_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01956-20","article-title":"First penicillin-binding protein occupancy patterns for 15 \u03b2-lactams and \u03b2-lactamase inhibitors in Mycobacterium abscessus","volume":"65","author":"Sayed","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.02.015_bib0018","series-title":"Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes","author":"Woods","year":"2011"},{"key":"10.1016\/j.jgar.2025.02.015_bib0019","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1099\/jmm.0.001224","article-title":"The rough colony morphotype of Mycobacterium avium exhibits high virulence in human macrophages and mice","volume":"69","author":"Nishimura","year":"2020","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jgar.2025.02.015_bib0020","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/JB.00606-10","article-title":"The peptidoglycan of Mycobacterium abscessus is predominantly cross-linked by L,D-transpeptidases","volume":"193","author":"Lavollay","year":"2011","journal-title":"J Bacteriol"},{"key":"10.1016\/j.jgar.2025.02.015_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JB.00760-17","article-title":"Two DD-carboxypeptidases from Mycobacterium smegmatis affect cell surface properties through regulation of peptidoglycan cross-linking and glycopeptidolipids","volume":"200","author":"Pandey","year":"2018","journal-title":"J Bacteriol"},{"key":"10.1016\/j.jgar.2025.02.015_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106669","article-title":"In vitro effects of diazabicyclooctane \u03b2-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex","volume":"60","author":"Misawa","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.02.015_bib0023","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/jac\/dkae288","article-title":"Dual \u03b2-lactams for the treatment of Mycobacterium abscessus: a review of the evidence and a call to act against an antibiotic nightmare","volume":"79","author":"Longo","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.02.015_bib0024","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00174-24","article-title":"In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus","volume":"68","author":"Chen","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.02.015_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106938","article-title":"In vitro susceptibility testing of imipenem-relebactam and tedizolid against 102 Mycobacterium abscessus isolates","volume":"62","author":"Burke","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.02.015_bib0026","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.2147\/IDR.S252485","article-title":"Antimicrobial susceptibility of Mycobacterium abscessus complex clinical isolates from a Chinese Tertiary Hospital","volume":"13","author":"Guo","year":"2020","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2025.02.015_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12941-023-00637-4","article-title":"Clinical characteristics and drug susceptibility profiles of Mycobacterium abscessus complex infection at a medical school in Thailand","volume":"22","author":"Sukmongkolchai","year":"2023","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jgar.2025.02.015_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02382-18","article-title":"Efficacy of Human-simulated epithelial lining fluid exposure of meropenem-nacubactam combination against class A","volume":"63","author":"Asempa","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.02.015_bib0029","first-page":"1581","article-title":"Spontaneous reversion of Mycobacterium abscessus from a smooth to a rough morphotype is associated with reduced expression of glycopeptidolipid and reacquisition of an invasive phenotype","volume":"152","author":"Howard","year":"2006","journal-title":"Microbiology (NY)"},{"key":"10.1016\/j.jgar.2025.02.015_bib0030","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/IAI.00835-06","article-title":"Hypervirulence of a rough variant of the Mycobacterium abscessus type strain","volume":"75","author":"Catherinot","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.jgar.2025.02.015_bib0031","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1128\/JCM.01478-08","article-title":"Acute respiratory failure involving an R variant of Mycobacterium abscessus","volume":"47","author":"Catherinot","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2025.02.015_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063237","article-title":"Molecular longitudinal tracking of Mycobacterium abscessus spp. during chronic infection of the human lung","volume":"8","author":"Kreutzfeldt","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2025.02.015_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0117657","article-title":"Mycobacterium abscessus morphotype comparison in a murine model","volume":"10","author":"Caverly","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2025.02.015_bib0034","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.chest.2019.03.019","article-title":"Mycobacterium bolletii lung disease in cystic fibrosis","volume":"156","author":"Rollet-Cohen","year":"2019","journal-title":"Chest"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525000499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525000499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:59:48Z","timestamp":1762610388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525000499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":34,"alternative-id":["S2213716525000499"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.02.015","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined dual \u03b2-lactams and diazabicyclooctane \u03b2-lactamase inhibitor is highly effective against Mycobacterium abscessus species in vitro","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}